Emcure Pharmaceuticals has entered into a strategic collaboration with Roche Pharma India to co-promote and expand access to advanced therapies for chronic kidney disease (CKD) and post-transplant immunosuppression. The partnership combines Emcure’s strong nephrology and transplant-focused sales force with Roche’s innovative portfolio including leading immunosuppressants and emerging CKD therapies aiming to improve patient outcomes, increase treatment adherence, and reach more nephrologists and transplant centres nationwide.
Glimpse:
The agreement, announced on January 27, 2026, focuses on Roche’s key products such as mycophenolate mofetil, everolimus, and investigational CKD therapies, which Emcure will actively co-promote through its specialised nephrology and transplant sales teams. The collaboration will also include joint medical education programmes, patient support initiatives, and efforts to raise awareness about early CKD detection and post-transplant care. The partnership is expected to benefit thousands of CKD and transplant patients by enhancing treatment access and adherence in both urban and tier-2/3 markets.
Emcure Pharmaceuticals and Roche Pharma India have joined forces in a strategic partnership to expand access to advanced therapies for chronic kidney disease (CKD) and solid organ transplantation across India. The collaboration, formalised on January 27, 2026, leverages Emcure’s extensive nephrology and transplant-focused sales network and deep market presence with Roche’s innovative portfolio of immunosuppressants and emerging CKD treatments.
Under the agreement, Emcure will actively co-promote Roche’s key products, including mycophenolate mofetil (CellCept), everolimus (Certican), and selected pipeline assets targeting CKD progression and transplant rejection. The partnership will focus on educating nephrologists, transplant surgeons, and physicians about optimal use of these therapies, improving adherence through patient support programmes, and driving earlier diagnosis and treatment initiation particularly in tier-2 and tier-3 cities where access to specialised care remains limited.
CKD affects an estimated 10–15% of India’s adult population, with diabetes and hypertension as leading causes. Late diagnosis and poor management frequently progress to end-stage renal disease, requiring dialysis or transplantation. Post-transplant care remains equally critical, with immunosuppression non-adherence contributing to graft loss and increased mortality. The Emcure Roche alliance aims to address these challenges by strengthening medical education, ensuring consistent supply, and supporting patients through counselling and adherence tools.
Emcure Pharmaceuticals leadership stated: “This partnership with Roche aligns perfectly with our mission to make high quality, innovative therapies accessible to every Indian patient who needs them. By combining our strong nephrology and transplant reach with Roche’s science-driven portfolio, we can make a meaningful difference in CKD and transplant outcomes nationwide.”
Roche Pharma India added: “India faces a growing burden of CKD and transplant-related challenges. Collaborating with Emcure allows us to extend the reach of our therapies while supporting the medical community with education and patient-centric solutions that improve long-term care.”
The collaboration will also include joint scientific symposia, CME programmes for nephrologists and transplant teams, and initiatives to raise awareness about early screening, lifestyle modification, and the importance of adherence in transplant patients. The partnership is expected to benefit thousands of patients annually by enhancing treatment availability, physician confidence, and patient support in both urban and underserved regions.
“CKD and transplantation require lifelong care and unwavering adherence. This partnership enables us to reach more patients with innovative therapies and comprehensive support ultimately helping more people live healthier, longer lives.”
By
HB Team
Related News
